• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

常规树突状细胞 1 亚群激活 CD8+ T 细胞并将肿瘤抗原转运至大脑以驱动抗肿瘤免疫。

The Conventional Dendritic Cell 1 Subset Primes CD8+ T Cells and Traffics Tumor Antigen to Drive Antitumor Immunity in the Brain.

机构信息

Department of Neurological Surgery, Washington University School of Medicine, St. Louis, Missouri.

Andrew M. and Jane M. Bursky Center for Human Immunology and Immunotherapy Programs, Washington University School of Medicine, St. Louis, Missouri.

出版信息

Cancer Immunol Res. 2023 Jan 3;11(1):20-37. doi: 10.1158/2326-6066.CIR-22-0098.

DOI:10.1158/2326-6066.CIR-22-0098
PMID:36409838
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10725570/
Abstract

The central nervous system (CNS) antigen-presenting cell (APC) that primes antitumor CD8+ T-cell responses remains undefined. Elsewhere in the body, the conventional dendritic cell 1 (cDC1) performs this role. However, steady-state brain parenchyma cDC1 are extremely rare; cDCs localize to the choroid plexus and dura. Thus, whether the cDC1 play a function in presenting antigen derived from parenchymal sources in the tumor setting remains unknown. Using preclinical glioblastoma (GBM) models and cDC1-deficient mice, we explored the presently unknown role of cDC1 in CNS antitumor immunity. We determined that, in addition to infiltrating the brain tumor parenchyma itself, cDC1 prime neoantigen-specific CD8+ T cells against brain tumors and mediate checkpoint blockade-induced survival benefit. We observed that cDC, including cDC1, isolated from the tumor, the dura, and the CNS-draining cervical lymph nodes harbored a traceable fluorescent tumor antigen. In patient samples, we observed several APC subsets (including the CD141+ cDC1 equivalent) infiltrating glioblastomas, meningiomas, and dura. In these same APC subsets, we identified a tumor-specific fluorescent metabolite of 5-aminolevulinic acid, which fluorescently labeled tumor cells during fluorescence-guided GBM resection. Together, these data elucidate the specialized behavior of cDC1 and suggest that cDC1 play a significant role in CNS antitumor immunity.

摘要

中枢神经系统 (CNS) 抗原呈递细胞 (APC) 启动抗肿瘤 CD8+ T 细胞反应的机制仍未确定。在身体的其他部位,传统树突状细胞 1 (cDC1) 发挥了这一作用。然而,静息状态下的脑实质 cDC1 极为罕见;cDC 定位于脉络丛和硬脑膜。因此,cDC1 是否在肿瘤环境中发挥作用,呈递源自实质来源的抗原仍不得而知。通过使用临床前胶质母细胞瘤 (GBM) 模型和 cDC1 缺陷小鼠,我们探索了 cDC1 在中枢神经系统抗肿瘤免疫中的目前未知作用。我们确定,除了浸润脑肿瘤实质本身外,cDC1 还能对脑肿瘤产生新抗原特异性 CD8+ T 细胞,并介导检查点阻断诱导的生存获益。我们观察到,从肿瘤、硬脑膜和中枢神经系统引流的颈淋巴结中分离出的 cDC,包括 cDC1,携带可追踪的荧光肿瘤抗原。在患者样本中,我们观察到几个 APC 亚群(包括 CD141+ cDC1 等效物)浸润胶质母细胞瘤、脑膜瘤和硬脑膜。在这些相同的 APC 亚群中,我们发现了 5-氨基乙酰丙酸的一种肿瘤特异性荧光代谢物,它在荧光引导的 GBM 切除过程中荧光标记肿瘤细胞。这些数据共同阐明了 cDC1 的特殊行为,并表明 cDC1 在中枢神经系统抗肿瘤免疫中发挥着重要作用。

相似文献

1
The Conventional Dendritic Cell 1 Subset Primes CD8+ T Cells and Traffics Tumor Antigen to Drive Antitumor Immunity in the Brain.常规树突状细胞 1 亚群激活 CD8+ T 细胞并将肿瘤抗原转运至大脑以驱动抗肿瘤免疫。
Cancer Immunol Res. 2023 Jan 3;11(1):20-37. doi: 10.1158/2326-6066.CIR-22-0098.
2
Are Conventional Type 1 Dendritic Cells Critical for Protective Antitumor Immunity and How?传统 1 型树突状细胞对保护性抗肿瘤免疫是否至关重要?以及如何发挥作用?
Front Immunol. 2019 Feb 12;10:9. doi: 10.3389/fimmu.2019.00009. eCollection 2019.
3
cDC1 Vaccines Drive Tumor Rejection by Direct Presentation Independently of Host cDC1.cDC1 疫苗通过独立于宿主 cDC1 的直接呈递驱动肿瘤排斥
Cancer Immunol Res. 2022 Aug 3;10(8):920-931. doi: 10.1158/2326-6066.CIR-21-0865.
4
T cell infiltration on local CpG-B delivery in early-stage melanoma is predominantly related to CLEC9ACD141 cDC1 and CD14 antigen-presenting cell recruitment.T 细胞浸润在早期黑色素瘤局部 CpG-B 递送上主要与 CLEC9ACD141 cDC1 和 CD14 抗原呈递细胞的募集有关。
J Immunother Cancer. 2021 Mar;9(3). doi: 10.1136/jitc-2020-001962.
5
Transcription factor Etv6 regulates functional differentiation of cross-presenting classical dendritic cells.转录因子 Etv6 调节交叉呈递经典树突状细胞的功能分化。
J Exp Med. 2018 Sep 3;215(9):2265-2278. doi: 10.1084/jem.20172323. Epub 2018 Aug 7.
6
Targeting BCL9/BCL9L enhances antigen presentation by promoting conventional type 1 dendritic cell (cDC1) activation and tumor infiltration.靶向 BCL9/BCL9L 通过促进常规型 1 型树突状细胞 (cDC1) 的激活和肿瘤浸润来增强抗原呈递。
Signal Transduct Target Ther. 2024 May 29;9(1):139. doi: 10.1038/s41392-024-01838-9.
7
cDC1 prime and are licensed by CD4 T cells to induce anti-tumour immunity.cDC1 呈递抗原并被 CD4 T 细胞许可,以诱导抗肿瘤免疫。
Nature. 2020 Aug;584(7822):624-629. doi: 10.1038/s41586-020-2611-3. Epub 2020 Aug 12.
8
Effective cancer immunotherapy by natural mouse conventional type-1 dendritic cells bearing dead tumor antigen.携带死肿瘤抗原的天然小鼠常规型 1 树突状细胞的有效癌症免疫疗法。
J Immunother Cancer. 2019 Apr 8;7(1):100. doi: 10.1186/s40425-019-0565-5.
9
Vaccine efficacy against primary and metastatic cancer with in vitro-generated CD103 conventional dendritic cells.体外生成的 CD103 常规树突状细胞对原发性和转移性癌症的疫苗疗效。
J Immunother Cancer. 2020 Apr;8(1). doi: 10.1136/jitc-2019-000474.
10
Tumor-targeted therapy with BRAF-inhibitor recruits activated dendritic cells to promote tumor immunity in melanoma.BRAF 抑制剂的肿瘤靶向治疗可募集激活的树突状细胞,促进黑色素瘤的肿瘤免疫。
J Immunother Cancer. 2024 Apr 17;12(4):e008606. doi: 10.1136/jitc-2023-008606.

引用本文的文献

1
Checkpoint antibody receptor modified ARMed CAR T circumvents the suppressive immunome in GBM.检查点抗体受体修饰的武装CAR T细胞可规避胶质母细胞瘤中的抑制性免疫组。
Front Immunol. 2025 Jul 31;16:1579925. doi: 10.3389/fimmu.2025.1579925. eCollection 2025.
2
Targeting the CD40 costimulatory receptor to improve virotherapy efficacy in diffuse midline gliomas.靶向CD40共刺激受体以提高弥漫性中线胶质瘤的病毒治疗疗效。
Cell Rep Med. 2025 Jul 15;6(7):102204. doi: 10.1016/j.xcrm.2025.102204. Epub 2025 Jun 26.
3
Barcoded viral tracing identifies immunosuppressive astrocyte-glioma interactions.条形码病毒示踪法鉴定免疫抑制性星形胶质细胞与胶质瘤的相互作用。
Nature. 2025 Jun 25. doi: 10.1038/s41586-025-09191-9.
4
Glioblastoma-instructed astrocytes suppress tumour-specific T cell immunity.胶质母细胞瘤诱导的星形胶质细胞抑制肿瘤特异性T细胞免疫。
Nature. 2025 May 21. doi: 10.1038/s41586-025-08997-x.
5
Antigen-presenting fibroblasts: emerging players in immune modulation and therapeutic targets.抗原呈递成纤维细胞:免疫调节中的新兴角色和治疗靶点。
Theranostics. 2025 Feb 18;15(8):3332-3344. doi: 10.7150/thno.104900. eCollection 2025.
6
Induction of macrophage efferocytosis in pancreatic cancer via PI3Kγ inhibition and radiotherapy promotes tumour control.通过抑制PI3Kγ和放疗诱导胰腺癌中的巨噬细胞吞噬作用可促进肿瘤控制。
Gut. 2025 Apr 7;74(5):825-839. doi: 10.1136/gutjnl-2024-333492.
7
Combination of tumor antigen drainage and immune activation to promote a cancer-immunity cycle against glioblastoma.联合肿瘤抗原引流和免疫激活以促进胶质母细胞瘤的癌症免疫循环。
Cell Mol Life Sci. 2024 Jun 22;81(1):275. doi: 10.1007/s00018-024-05300-5.
8
Immunotherapy for Brain Tumors: Where We Have Been, and Where Do We Go From Here?脑肿瘤的免疫治疗:我们从哪里来,又将走向何方?
Curr Treat Options Oncol. 2024 May;25(5):628-643. doi: 10.1007/s11864-024-01200-9. Epub 2024 Apr 23.
9
Enhanced oral versus flank lymph node T cell response parallels anti-PD1 efficacy in head and neck cancer.增强口腔与侧腹淋巴结 T 细胞应答与头颈部肿瘤抗 PD-1 疗效平行。
Oral Oncol. 2024 May;152:106795. doi: 10.1016/j.oraloncology.2024.106795. Epub 2024 Apr 9.
10
Immunotherapy in the context of immune-specialized environment of brain metastases.脑转移瘤免疫特异性环境下的免疫治疗
Discov Immunol. 2023 Nov 16;2(1):kyad023. doi: 10.1093/discim/kyad023. eCollection 2023.

本文引用的文献

1
Single-cell profiling of human dura and meningioma reveals cellular meningeal landscape and insights into meningioma immune response.单细胞分析人类硬脑膜和脑膜瘤揭示细胞脑膜景观,并深入了解脑膜瘤免疫反应。
Genome Med. 2022 May 10;14(1):49. doi: 10.1186/s13073-022-01051-9.
2
Characterization of the Genomic and Immunologic Diversity of Malignant Brain Tumors through Multisector Analysis.通过多领域分析对恶性脑肿瘤的基因组和免疫多样性进行特征分析。
Cancer Discov. 2022 Jan;12(1):154-171. doi: 10.1158/2159-8290.CD-21-0291. Epub 2021 Oct 5.
3
GATA2 Regulates Constitutive PD-L1 and PD-L2 Expression in Brain Tumors.GATA2 调控脑肿瘤中 PD-L1 和 PD-L2 的组成性表达。
Sci Rep. 2020 Jun 3;10(1):9027. doi: 10.1038/s41598-020-65915-z.
4
Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions.成人脑胶质母细胞瘤:神经肿瘤学会(SNO)和欧洲神经肿瘤学会(EANO)关于当前管理和未来方向的共识综述。
Neuro Oncol. 2020 Aug 17;22(8):1073-1113. doi: 10.1093/neuonc/noaa106.
5
A conserved dendritic-cell regulatory program limits antitumour immunity.一个保守的树突状细胞调控程序限制了抗肿瘤免疫。
Nature. 2020 Apr;580(7802):257-262. doi: 10.1038/s41586-020-2134-y. Epub 2020 Mar 25.
6
Treatment of an aggressive orthotopic murine glioblastoma model with combination checkpoint blockade and a multivalent neoantigen vaccine.采用联合检查点阻断和多价新抗原疫苗治疗侵袭性原位小鼠胶质母细胞瘤模型。
Neuro Oncol. 2020 Sep 29;22(9):1276-1288. doi: 10.1093/neuonc/noaa050.
7
VEGF-C-driven lymphatic drainage enables immunosurveillance of brain tumours.VEGF-C 驱动的淋巴引流使脑肿瘤能够进行免疫监视。
Nature. 2020 Jan;577(7792):689-694. doi: 10.1038/s41586-019-1912-x. Epub 2020 Jan 15.
8
Cryptic activation of an Irf8 enhancer governs cDC1 fate specification.IRF8 增强子的隐匿激活控制 cDC1 命运特化。
Nat Immunol. 2019 Sep;20(9):1161-1173. doi: 10.1038/s41590-019-0450-x. Epub 2019 Aug 12.
9
Meningeal lymphatic vessels at the skull base drain cerebrospinal fluid.颅底脑膜淋巴管引流脑脊液。
Nature. 2019 Aug;572(7767):62-66. doi: 10.1038/s41586-019-1419-5. Epub 2019 Jul 24.
10
Unleashing Type-2 Dendritic Cells to Drive Protective Antitumor CD4 T Cell Immunity.释放 2 型树突状细胞以驱动保护性抗肿瘤 CD4 T 细胞免疫。
Cell. 2019 Apr 18;177(3):556-571.e16. doi: 10.1016/j.cell.2019.02.005. Epub 2019 Apr 4.